Question

 

In the natural history of a disease define total preclinical phase, detectable pre-clinical phase and clinical phase. Suppose on 09 am on 25.01.2024 a disease A onset you biologically. Suppose a test of disease A can detect it exactly after the completion of 30 days of biological onset. Suppose signs and symptoms develop exactly after the completion of 34 days of biological onset. Suppose you consult a doctor exactly after 37 days of the biological onset of the disease. Suppose the outcome of the treatment is the cure. What is the duration of the (i)total preclinical phase (ii) detectable pre-clinical phase (iii) clinical phase?

18 Apr 2025
Answer :
Word Count : 506

In epidemiology and clinical trials, understanding the natural history of a disease is crucial for analyzing the progression of disease, timing of interventions, and assessing the effectiveness of diagnostic tests and treatments. The natural history of a disease includes several phases: the total preclinical phase, the detectable pre-clinical phase, and the clinical phase. These phases define the progression of the disease from its biological onset to the point at which symptoms appear, diagnosis is made, and treatment outcomes are assessed.

Total Preclinical Phase: This phase includes the time from the biological onset of the disease until the appearance of clinical signs __________ _______ _________ ______ ____ ___ ______ _____ __________.
____ _____ _____ _________ ___ _________ _____ _____ _________ _________.
________ ____ __________ ____ _______ ______ __________ ___ _________ ___ ____.
______ ________ __________ _____ _______.
_______ __________ __________ ____ _________ ______ ___ ________ ________ ____ _____ _____.
______ _______ __________ ________ _________ ___ ______ __________ __________ ___.
________ _________ _____ _________ __________ __________.
_________ ___ ___ _____ ____ _______ __________ ____.
______ ________ _____ ____ __________ ________ ____ _____.
______ ______ ___ _____ _____ _____.
_____ _________ _______ _________ ___ ______ _________.
__________ _________ ______ _______ ____ ________.
________ ___ ___ ________ ________ _________ _____ ____ _______ __________ ______.
_________ ___ ________ ___ ______ ________ ________ ____ ___.
_________ _______ ____ _____ _______ _______ ________ _____ _____ ____.
__________ __________ _____ ___ ________ _______ ______ ______ ____ ___.
________ _______ ____ ______ ________ ____ ______ _______.
_______ ___ _____ ______ ___ ____ ______ ___ ___ _________.
________ ___ ______ _______ __________ ________ _____ _______ _____.
_____ ___ _____ ____ ____ ___ ___ ___ _____ _________ _______.
_______ _____ ___ _______ _______ _______ _______ __________ _____ ________.
_____ ______ _________ _______ ______ _______ __________.
__________ ________ ___ ________ _______ _______.
_____ _________ _______ _________ ___.
____ ________ ______ __________ ____ _____ ______.
________ _______ ______ _____ ________ __________ _____ ___ _____ _______ ______ _______.
_______ ___ ________ _____ ____.
_____ ____ ___ _________ __________ ____ ___ _______ _____ ____.
_____ ______ __________ ______ __________ ___ __________.
___ ________ _________ ___ _________ ___ ___ ___ ______ _______ ____ _______.
___ ____ _____ ______ ______ ____ ________ _______.
_______ _______ ___ ______ _______.
___ _______ _________ ______ ________ __________.
_________ __________ ___ ____ ________ ______.
____ _________ _________ __________ ___ ______ ___ _______.
__________ ___ _____ _________ _____ ________ __________ _________ _____ ________ ___.
_____ _______ __________ ________ ________ __________ ____ ______ __________ ____.
_________ _______ ____ _____ _________ ________ ___ ____ ___.
________ _______ _______ ______ _____ _____.
__________ _______ _____ ____ __________ _______ _____ _________ _______.
______ ______ ______ ________ ________ ________ __________ _____ ________ _________.
________ _______ ________ _______ ________ _____ _________ ___.
_____ ________ ___ __________ ___ ________ _____ _______ __________ _______ ______.
________ __________ ____ _________ ________ __________.
__________ ____ ______ _______ ________ _______ ________ _______ ________ ____ __________ ________.
_______ ________ ___ _____ ___ ___ _____ ________ _________ ______ _____ _____.
_________ ______ _________ _____ _____ __________ __________ _______ ____ ________ _____.
Get Full Answer on WhatsApp

Related Questions

If p denotes proportion and q denotes odds then prove that  Find the range of q. If the odds of smokers in a study are 0.75 then find the proportion of smokers in the study. Assume that each subject of the study is either a smoker or a non-smoker.

 

If you are told that hemoglobin (Hb) level in blood measures the iron content. The normal level in healthy people is around 15 g/dL. Most Indian women have less and some have even less than 8 g/dL. They are called anemic. Iron supplementation is given to increase this level. Suppose one supplementation increases the mean Hb level in anemics by 3.2 g/dL, after one month of use and the other by 3.6 g/dL, in an equivalence trial on 500 women each. The respective SD's of the of the increases are 0.52 and 0.72 g/dL. The doctors determine that the supplementations can be clinically equivalent if the difference between the increases by the two supplementations does not exceed 0.52 g/dL. Can these two supplementations be considered clinically equivalent at 5% level of significance?

 

Explain the entire procedure of any one of the three study designs (a) Cross Sectional (b) Cohort (c) Case Control.

A trial is conducted in which some people with disease X were randomly allocated into two groups. The first group was advised to do some morning walks for 30 minutes and take light food each day and the second group was given one injection and one 100 mg tablet once a day to control disease X. The injection can cause loose motion in some cases and 100 mg tablet has no side effect. At the end of two months, 90% of group I and 80% of group II had recovered from disease X.

i) What are the regimens for group I and group II in this trial?

 

ii) What are the efficacies in group I and group II?

 

iii) What are the safety issues in group I and group II in this trial?

 

In the natural history of a disease define total preclinical phase, detectable pre-clinical phase and clinical phase. Suppose on 09 am on 25.01.2024 a disease A onset you biologically. Suppose a test of disease A can detect it exactly after the completion of 30 days of biological onset. Suppose signs and symptoms develop exactly after the completion of 34 days of biological onset. Suppose you consult a doctor exactly after 37 days of the biological onset of the disease. Suppose the outcome of the treatment is the cure. What is the duration of the (i)total preclinical phase (ii) detectable pre-clinical phase (iii) clinical phase?

IGNOU Solved Assignments Assignments Ignou Projects Project Previous Year Solved Exam Papers Notes Notes Sample Question Papers Sample Question Papers
Login Cart
IGNOU NEWS
Assignment Submission Last Date Extended Till 30 June 2026 Click Here★★★IGNOU June 2026 TEE Date Sheet Released Click Here★★★
Top
📞
Call Support Instant phone assistance  In the natural history of a disease define total preclinical
→
🟢
WhatsApp Chat Fast live messaging
→
Email Us Business enquiries & support
→